“Science has the power to change the world for the better.  In our industry, we are lucky that we are sometimes able to that we are sometimes able to translate our sciences into medicines that can transform the lives of millions of patients.”

MENE PANGALOS, AstraZeneca Executive Vice President of BioPharmaceuticals Research and Development, speaking in a video that AstraZeneca created on the occasion of and to tell the news of Mr. Panagalos being knighted by Her Majesty Queen Elizabeth II for his contributions to United Kingdom science.  The honor was bestowed as a component of Her Majesty’s 2020 Honours List

(Header image: AstraZeneca R&D Centre and Global Headquarters in Cambridge, UNITED KINGDOM; image credit: AstraZeneca.)

AstraZeneca, based in England, is one of the leading international pharmaceutical corporations.

The company was formed in 1999 with the merger of Swedish Astra AB and the English Zeneca Group.

For several years it has been the privilege of Willwork Global Event Services to provide tradeshow and event services to AstraZeneca.

Accordingly, and most appropriately, Willwork enthusiastically highlights and spreads the word of the winning performance of AstraZeneca in 2019 – a performance that continues into 2020 with increased strength and growing momentum.

Of course, this success and achievement means, for those afflicted and suffering from serious illness, longer and improved quality of life, and hope.


On the second-to-last day of 2019, the U.S. Food and Drug Administration (FDA) announced that it approved, to treat pancreatic cancer, a drug co-developed by AstraZeneca and Merck.

The medication – LYNPARZA® – already effective in the treatment of other types of cancer, is in the drug class PARP inhibitors.

Please click here to be taken to a story, “FDA Approves AstraZeneca and Merck’s Lynpraza for pancreatic cancer,” written by Alex Keown, and published in BioSpace, a digital media outlet covering the life sciences industry.

This news came 10 days after the FDA approved ENHERTU® – a medicine AstraZeneca developed in collaboration with Japanese drug maker Daiichi Sankyo – to treat inoperable and metastatic breast cancers.

Clicking here transports you to the FDA announcement of its approval of ENHERTU®.

AstraZeneca has long been involved in the battle to take down breast cancer.

Almost 50 years ago, AstraZeneca produced the first drug to treat the disease. 

Today the company has six breast cancer drugs available, and nine breast cancer drugs in the development pipeline. 

As well, AstraZeneca has played a broader role in the quest to defeat and find a cure for breast cancer. 

AstraZeneca was one of the founders of Breast Cancer Awareness Month, as we detailed in the post, “Willwork Global Event Services Clients are Leading in Breast Cancer Prevention, Diagnosis, Treatment … and the Quest to Find the Cure,”, published on this blog on October 31.

Now, consider that even before the FDA approved LYNPARZA® and ENHERTU®, 2019 had been a championship year for AstraZeneca.

Indeed, three days prior to the FDA releasing its ENHERTU® news, BioPharma Dive – a newsletter and website that covers the biotech and pharma industries, and which has a reader and viewer base of seven million – published a story in which it named AstraZeneca “Pharma of the Year.”  

This recognition continues a run of positive results for AstraZeneca that commenced in 2012 when Pascal Soriot came on board as CEO of the company.    

The following excerpt from the BioPharma Dive story, which is authored by Jonathan Gardner, presents and frames a perspective that takes in Mr. Soriot’s arrival at AstraZeneca and the seven-year stretch that brings us to the fourth quarter of 2019:

“This year, five of AstraZeneca’s blockbusters are growing, while in 2012 five of its seven were in retreat, taking $4.4 billion from its top line.  The company can now confidently point to growing sales, with revenue $2.2 billion greater over the first nine months of the year versus the same period in 2018.”

Please click here to be taken to the complete BioPharma Dive article.


You know it has been a good year for an organization when the monarch of the United Kingdom, Her Majesty Queen Elizabeth IIknights one of its employees.

Below we share the first paragraph of an article, “AstraZeneca scientist knighted,” published in The Pharma Letter on the final day of 2019:

“Mene Pangalos … one of the leaders behind AstraZeneca’s (LSE: AZN) remarkable recent record of successful drug development, has been awarded a knighthood.”

Mene Pangalos is the Executive Vice President of BioPharmaceuticals Research and Development at AstraZeneca.

Sir Mene Pangalos, Executive Vice President of Research and Development at AstraZeneca (image credit: The Pharma Letter)

Mr. Pangalos – who is now, by virtue of being knighted, Sir Pangalos – received from Queen Elizabeth II the award and distinction as a component of the 2020 edition of New Year Honours, a UK institution which goes back to 1890, and by which or in the name of the monarch of England, or the vice-regal representative of the monarch, honors are bestowed for contributions and service to the UK.

Willwork Global Event Services recommends an AstraZenca video – which can be accessed by clicking here – in which Sir Pangalos expresses his gratitude and appreciation for the honor of knighthood.

In the video, Sir Pangalos also gives thanks for having a job and a career that he loves and which fulfills him, with these benefits – as he explains – provided through the work goals he pursues, the extraordinary people with whom he collaborates, and the teams and team environment of which he is a member.

Sir Pangalos knows he is part of a great group doing among the most important work on earth. 

Willwork Global Event Services looks forward to continuing to support and provide services for this great group – the great group AstraZeneca.

A Man, a Giant Pumpkin, a River – and a World Record

(Header image: Todd Sandstrum en route to the world record)

Willwork Global Event Services, founded in 1987, is a leading exhibition services and event project management company.

In our social media posts, we like to talk about and point to events, exhibitions, conventions, parties, soirees, shows, and festivals … of all types.

Indeed, here in this space, among the topics we have featured and discussed are the summer solstice, celebrations held for championship professional sports teams, “Blood Moon,”  World’s Columbian Exposition (more commonly called the 1893 Chicago World’s Fair), Halloween and scary-themed expositions and events, world’s top flower shows, and giant and spectacular Christmas trees.

This being the first week of October and early fall, we thought it particularly appropriate to herald an event which is built around and promotes a fruit – a cultivated and domesticated fruit that is member of the winter squash family.

Yes, we are talking about the pumpkin – a native of North America, originating about 7,000 BC, in an area that encompasses present day northeastern Mexico and southern United States.

Getting back to squashes – the pumpkin is also a gourd, which is an ornamental squash, even if pumpkins are also a favorite food source, whereas most ornamental squashes are edible, but intensely bitter.

Willwork Global Event Services has a direct tie to a big-time event involving a pumpkin. 

Actually, we refer to a world record involving a pumpkin – a really big pumpkin – that was established by a native of Easton, MA, the town where is located the Willwork Global Event Services corporate office.

The Easton native is Todd Sandstrum, a gentleman who was also living in Easton when, on September 3, 2016, he set the global mark.

Mr. Sandstrum – a third-generation farmer, agricultural steward and education advocate, and environmentalist – made it into the Guinness World Records when he skippered and paddled a 1,240-lb. pumpkin, carved and fashioned into a boat, eight miles on the Taunton River, a waterway in southeastern Massachusetts.

The Taunton River is 36 miles long, from its origin in the town of Bridgewater, MA to where it meets the Atlantic Ocean in Mount Hope Bay at the border of Massachusetts and Rhode Island.

Starting in the city of Taunton, the Taunton River is tidal for the final 12 miles of its journey to the ocean.

Success came for Mr. Sandstrum a year after his first pumpkin-paddling world record attempt – also on the Taunton River.  In that effort, he made it about 3.5 miles before shallow water halted his progress.

Yet, that 3.5-mile trek was recognized as a world record by the World Record Academy.  Guinness, though, did not certify the mark because of insufficient documentation.

Todd Sandstrum’s second try for a world best would be thoroughly chronicled, with local media covering the event. 

Mr. Sandstrum set his pumpkin boat in the water in Dighton, MA.

His final destination was Battleship Cove, a maritime museum and war memorial set in Fall River. MA at the intersection of the Taunton River and the Atlantic. 

Approximately four hours and 13 minutes after he set off from Dighton, hundreds were cheering from the shoreline, and news cameras clicked and rolled, as Todd Sandstrum pulled his pumpkin vessel up next to the USS Massachusetts (which is permanently anchored at Battleship Cove) and affixed a kiss to the famed and iconic battleship.

Mission Complete – Todd Sandstrum kisses the USS Massachusetts (image credit: Marc Vasconcellos for the The Enterprise)

One for the record books.

To learn more about Todd Sandstrum’s world record, please click here to be taken to an Enterprise newspaper story, smartly titled, “Good gourd! Easton man paddles pumpkin boat, squashes record,” written by Cody Shepard, with photos by Marc Vasconcellos.